Predictive Factors Study

• Status: Terminated
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a long term study to evaluate common therapeutic algorithms and possible predictive parameters for Somatuline Autogel treatment in patients with Acromegaly.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen
• Treatments: Angiopeptin; Lanreotide; Somatostatin

Criteria

Inclusion Criteria:

• Diagnosis of Acromegaly.

• Males and females aged 18 years and older.

• Signed informed consent (patient must give consent to the collection of retrospective data).

• Patients who have had surgery may enter the study 3 months post-surgery and evaluated for the duration of the study.

• With the intention to be treated with ATG (decision to prescribe ATG made prior to inclusion into the study) or already being treated with ATG.

• If already being treated with ATG:

Previous ATG treatment maximum of 3 months. AND Minimum data available (demographic data, disease history including previous treatments, GH, IGF-1 levels at baseline and under treatment as applicable).

• Not receiving Dopamine Agonists or other medical therapy (Pegvisomant, or other somatostatin analogues) for the treatment or symptom control of acromegaly.

Exclusion Criteria:

• The subject has had radiotherapy in the last 5 years.

• The subject has had surgery in the last 3 months.

• The subject has already been included in this study.

• Participation in an interventional trial, or receiving experimental drug.